Diurnal Group PLC Hardman Research: Infacort® - On track to market
19 January 2017 - 6:15PM
RNS Non-Regulatory
TIDMDNL
Diurnal Group PLC
19 January 2017
Hardman Research: Infacort(R) - On track to market
Infacort(R) - On track to market: Diurnal is a clinical stage
specialty pharmaceutical company focused on diseases of the
endocrine system. It has two lead candidates - Infacort that
completed its Phase III in Dec 2016 and Chronocort, currently in
Phase III trials - targeted at rare diseases with unmet medical
need, and is aiming to build a long-term 'Adrenal Franchise'. The
completed Phase III trial confirmed that Infacort is well
tolerated, achieved its primary endpoint and received the support
of the parents and carers. Infacort will represent the first
licenced cortisol replacement therapy for children and is on track
to achieve market authorisation in late 2017 and sales in early
2018.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/19.01.17-infacort-on-track-to-market.pdf
To contact us: Contact: Dr Martin Hall
Hardman & Co mh@hardmanandco.com
11/12 Tokenhouse Dr Dorothea Hill
Yard dmh@hardmanandco.com
London Dr Gregoire Pave
EC2R 7AS gp@hardmanandco.com
Telephone: +44 20 7929 3399
Follow us on Twitter @HardmanandCo
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAVVLFFDFFFBBD
(END) Dow Jones Newswires
January 19, 2017 02:15 ET (07:15 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024